150
Viral Infections: Clinical Trials and Pathogenesis
Friday, October 10, 2014: 2:00 PM-3:30 PM
Room: The Pennsylvania Convention Center: 105-AB
Target Audience: Academicians, Clinicians, Fellows, Infectious diseases pediatricians, Investigators, Medical students and residents, Members-in-training, Microbiologists, Researchers, Scientists
Tracks: Adult ID, Investigative ID, Pediatric ID
Moderators:
Mark Sulkowski, MD, Johns Hopkins University School of Medicine
and
Ajit Limaye, MD, FIDSA, University of Washington
Presentations:
2:00 PM
ABT-450/r/Ombitasvir and Dasabuvir with Ribavirin Achieves High Sustained Virologic Response Rates Regardless of Baseline Characteristics: Pooled Analyses of the SAPPHIRE-I and SAPPHIRE-II Studies
Jordan J. Feld, MD, MPH
;
Ola Weiland, MD
;
Rui Tato Marinho, MD, PhD
;
Heiner Wedemeyer, MD
;
Ira M. Jacobson, MD
;
Donald M. Jensen, MD
;
Tarek Hassanein, MD
;
Victor De Ledinghen, MD
;
Moisés Diago, MD
;
Lorenzo Magenta, MD
;
Robert J. De Knegt, MD
;
Junyuan J. Xiong, MS
;
Eoin Coakley, MD
;
Tolga Baykal, MD
;
Fernando Tatsch, MD
;
Graham R. Foster, FCRP
2:15 PM
Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis
Mark Sulkowski, MD
;
Kris Kowdley, MD
;
Peter Ruane, MD
;
Trevor Hawkins, MD
;
Richard Elion, MD
;
Kimberly Workowski, MD
;
Anthony Mills, MD
;
Mani Subramanian, MD, PhD
;
Xiao Ding, PhD
;
Star Seyedkazemi, PharmD
;
Robert H. Hyland, D.Phil
;
Jenny C. Yang, PharmD
;
Phillip S. Pang, MD, PhD
;
John G. Mchutchison, MD
;
Nezam Afdhal, MD
;
David Wyles, MD
2:30 PM
Defining herpes simplex virus type 2 sequence heterogeneity using next generation sequencing
Christine Johnston, MD, MPH
;
Amalia Magaret, PhD
;
Kurt Diem
;
Matthew Fitzgibbon
;
Meei-Li Huang, PhD
;
Stacy Selke, MS
;
Anna Rashevsky
;
Jairam Lingappa, MD, PhD
;
Connie Celum, MD, MPH
;
David M. Koelle, MD
;
Anna Wald, MD, MPH, FIDSA
2:45 PM
Co-Reactivation of Human Herpesvirus 6 (HHV-6) and Cytomegalovirus (CMV) is Associated with Worse Clinical Outcome in Critically Ill Immunocompetent Adults
Joshua Hill, MD
;
Paula Roa, PharmD
;
Katharine Kirby, MSc
;
Meei-Li Huang, PhD
;
Tracy Santo, BSc
;
Keith Jerome, MD, PhD
;
Michael Boeckh, MD
;
Ajit Limaye, MD, FIDSA
CME Credits:
ACPE Credits:
ACPE Number:
Disclosures:
M. Sulkowski,
AbbVie: Investigator and Scientific Advisor, Consulting fee and Research grant
BMS: Investigator and Scientific Advisor, Consulting fee and Research support
Gilead: Investigator and Scientific Advisor, Consulting fee and Research support
Janssen: Investigator and Scientific Advisor, Consulting fee and Research support
Merck: Investigator and Scientific Advisor, Consulting fee and Research support
A. Limaye,
Genentech: Consultant and Grant Investigator, Consulting fee
Merck: Grant Investigator, Consulting fee
Viropharma: Grant Investigator, Contracted research
Astellas: Grant Investigator, Contracted research
BioRad: Consultant, Consulting fee
